Driving personalized medicine: Capturing maximum net present value and optimal return on investment

Personalized Medicine

Volumn 7, Issue 1, 2010, Pages 103-114

  Roth, Mollie ^a   Keeling, Peter ^a   Smart, Dave ^a  

^a Diaceutics ^*  (United Kingdom)

Author keywords

Benchmark; Companion diagnostic; Drivers; Financial metrics; Model; Net present value; NPV; Personalized medicine; Return on investment; ROI; Targeted therapy

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALENDRONIC ACID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ERLOTINIB; INSULIN; LAPATINIB; PIOGLITAZONE; TRASTUZUMAB;

ARTICLE; BIOMETRY; CLINICAL PROTOCOL; DIABETES MELLITUS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG TARGETING; EVIDENCE BASED PRACTICE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INVESTMENT; LIFE CYCLE; MARKETING; MEDICINE; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

EID: 74049119340     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.09.64     Document Type: Article

References (21)

1. Epstein RS, Frueh FW, Geren D et al.: Payer perspectives on pharmacogenomics testing and drug development. Pharmacogenomics 10(1), 149-151 (2009).
2. Keckly P: The ROI For Targeted Therapies: A Strategic Perspective. Deloitte Center for Health Solutions, Washington DC, USA (2009).
3. Davis JC, Furstenthal L, Desai AA et al.: The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 8(4), 279-286 (2009).
4. Phillips KA, Liang SY, Van Bebber S; Canpers Research Group: Challenges to the translation of genomic information into clinical practice and health policy: utilization, preferences and economic value. Curr. Opin. Mol. Ther. 10(3), 260-266 (2008).
5. Vernon JA, Johnson SJ, Hughen WK, Trujillo A: Economic and developmental considerations for pharmacogenomic technology. Pharmacogenomics 24(4), 335-343 (2006).
6. Stallings SC, Witt WP, Crown WH et al.: An economic framework for evaluating personalized medicine. Sloan Industry Studies Working Papers WP-2004-2003 (2004).
7. DiMasi JA, Seibring MA, Lasagna L: New drug development in the United States from 1963 to 1992. Clin. Pharmacol. Ther. 55, 609-622 (1994).
8. Kaitin KI, DiMasi JA: Measuring the pace of new drug development in the user fee era. Drug Inf. J. 34, 673-680 (2000).
9. The pink sheet, targeted therapies could make Rx companies more credible. 68(26), 22 (2006).
10. The intended use statement for the NCP was: "The NCP is indicated as an aid in the assessment of patients for whom NCT treatment is being considered".
11. We note that all ROI/NPV analyses are highly sensitive to the cost of capital and discount rate assumptions; for example, a 4% increase in the cost of capital removes US$129 million from all of our drivers' NPV.
12. Vernon JA, Johnson SJ, Hughen WK, Trujillo A: Economic and developmental considerations for pharmacogenomic technology. Pharmacogenomics 24(4), 335-343 (2006).
13. Keeling P, Roth M: Getting Personalized. Pharmaceutical Executive October (2008).
14. Woelderink A, Ibarreta D, Hopkins MM, Rodriguez-Cerezo E: The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J. 6, 3-7 (2005).
15. Smith D: Compliance packaging: a patient education tool. Am. Pharm. NS29(2) 42-45, 49-53 (1989).
16. Schering Report IX: The forgetful patient: the high cost of improper patient compliance. (1997).
17. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA: Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am. J. Health Syst. Pharm. 62, 1468-1475 (2005).
18. Pickering L: Companion diagnostics: enabling personalized medicine in cancer. Spectrum Reports, Biomarkers and Diagnostic, 27 October (2006).
19. Dutton G: Molecular diagnostics as clinical tools: new applications help research advance to full bedside utility, genetic engineering and biotechnology news www.genengnews.com/articles/chitem.aspx?aid=852&chid=1
20. IMS Advanced Oncology Analyzer, MAT Q3 (2007) http://imsoncology.com/ Media/imsoncology eu.pdf
21. Diffusion and use of genomic innovations in health and medicine: workshop summary, translation of genomic technology at the clinical level, a primary care provider view of translating genomic innovation, conversation with Dr Steven Shak of genomic health www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book= nap12148&part=a200150e2ddd00031.